1-20 of 28
Authors: Dietmar Krex
Journal Article
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide Get access
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 557–566, https://doi.org/10.1093/neuonc/noae205
Published: 01 October 2024
Journal Article
PATH-19. PROGNOSTIC FACTORS, RESPONSE TO TREATMENT, AND OUTCOME OF PATIENTS WITH ISOCITRATE DEHYDROGENASE (IDH)-MUTANT ASTROCYTOMA, CNS WHO GRADE 4
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v171, https://doi.org/10.1093/neuonc/noad179.0649
Published: 10 November 2023
Journal Article
CTNI-65. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v91–v92, https://doi.org/10.1093/neuonc/noad179.0347
Published: 10 November 2023
Journal Article
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii66, https://doi.org/10.1093/neuonc/noac209.259
Published: 14 November 2022
Journal Article
CTNI-29. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii77, https://doi.org/10.1093/neuonc/noac209.294
Published: 14 November 2022
Journal Article
NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii169–vii170, https://doi.org/10.1093/neuonc/noac209.650
Published: 14 November 2022
Journal Article
CTNI-38. PriCoTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi68, https://doi.org/10.1093/neuonc/noab196.263
Published: 12 November 2021
Journal Article
BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi11, https://doi.org/10.1093/neuonc/noab196.039
Published: 12 November 2021
Journal Article
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii14, https://doi.org/10.1093/neuonc/noaa215.056
Published: 09 November 2020
Journal Article
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi25–vi26, https://doi.org/10.1093/neuonc/noz175.095
Published: 11 November 2019
Journal Article
INNV-04. IDH MUTATION PREDICTION IN GLIOMA: A MULTIMODAL APPROACH
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi131, https://doi.org/10.1093/neuonc/noz175.547
Published: 11 November 2019
Journal Article
TMIC-38. ENHANCED EFFICACY OF TUMOR TREATING FIELDS AND AURORA B KINASE INHIBITOR COMBINATION IN GLIOMA CELL LINES
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi264, https://doi.org/10.1093/neuonc/noy148.1097
Published: 05 November 2018
Journal Article
QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi218–vi219, https://doi.org/10.1093/neuonc/noy148.906
Published: 05 November 2018
Journal Article
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi8–vi9, https://doi.org/10.1093/neuonc/noy148.028
Published: 05 November 2018
Journal Article
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Neuro-Oncology, Volume 20, Issue 7, July 2018, Pages 975–985, https://doi.org/10.1093/neuonc/nox204
Published: 07 November 2017
Journal Article
ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi5–vi6, https://doi.org/10.1093/neuonc/nox168.018
Published: 06 November 2017
Journal Article
ACTR-52. CLINICAL IMPACT OF TERT PROMOTER DETECTION IN CIRCULATING CELL-FREE DNA OF PATIENTS WITH GLIOBLASTOMA – A PILOT STUDY
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi12, https://doi.org/10.1093/neuonc/nox168.043
Published: 06 November 2017
Journal Article
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi13–vi14, https://doi.org/10.1093/neuonc/nox168.049
Published: 06 November 2017
Journal Article
QLIF-38. TUMOR TREATING FIELDS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME IN DAILY PRAXIS: EXPERIENCE FROM TWO HOSPITALS IN GERMANY
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi209–vi210, https://doi.org/10.1093/neuonc/nox168.847
Published: 06 November 2017
Journal Article
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Neuro-Oncology, Volume 20, Issue 3, March 2018, Pages 367–379, https://doi.org/10.1093/neuonc/nox160
Published: 24 August 2017
